Compare Bilibili Inc (BILI) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bilibili Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Bilibili Inc trades at $18.36 (market cap $7.35B), while State Street SPDR S&P Biotech ETF trades at $155.14. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | XBI | |
|---|---|---|
Market Cap | $7.35B | — |
Sector | Media | Broad Market / Factor |
52-Week High | $35.92 | $164.28 |
52-Week Low | $15.96 | $85.16 |
Enterprise Value | $5.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.59, down 0.62% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.19, beating expectations, and maintains strong analyst support with 83.3% buy ratings. Revenue growth is steady, projected at $30.8B for 2026, with improving net income margins. Recent news highlights a new $300 million share repurchase program, signaling confidence in long-term value.
The outlook for BILI is cautiously optimistic, driven by earnings beats and shareholder-friendly actions, but risks include competitive pressures in the Chinese digital media space and technical bearishness. Upside potential hinges on sustained user growth and margin expansion, while volatility from market sentiment poses a near-term challenge.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
